XML 113 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment Information (Notes)
 12 Months Ended
Dec. 31, 2012
Segment Reporting [Abstract]  
Segment Information

The Company is organized in two operating segments, Long-Term Care Group ("LTC") and Specialty Care Group ("SCG"). These segments are based on the operations of the underlying businesses and the customers they serve. The Company's larger reportable segment is LTC, which primarily provides distribution of pharmaceuticals, related pharmacy consulting and other ancillary services and medical supplies. LTC's customers are primarily skilled nursing, assisted living and other providers of healthcare services. The Company’s other reportable segment is SCG, which provides specialty pharmacy, key commercialization services for the biopharmaceutical industry and end-of-life pharmaceutical care management for hospice care agencies. The primary components of the "Corporate/Other" segment are the Company's corporate management oversight and administration, including its information technology and data management services, as well as other consolidating and eliminating entries, which have not been charged to reportable segments. The Company evaluates the performance of its segments based on revenue and operating income, and does not include segment assets or nonoperating income/expense items for management reporting purposes.

The table below presents information about the segments as of and for the years ended December 31, 2012, 2011 and 2010 (in thousands):

 
 
For the years ended December 31,
2012:
 
LTC
 
SCG
 
Corporate/Other
 
Consolidated
Totals
Net sales
 
$
4,848,341

 
$
1,301,761

 
$
10,286

 
$
6,160,388

Depreciation and amortization expense
 
(69,818
)
 
(15,595
)
 
(50,528
)
 
(135,941
)
Settlement, litigation and other related charges
 
(49,175
)
 
(200
)
 
—

 
(49,375
)
Other charges, net
 
(2,568
)
 
(2,090
)
 
(63,145
)
 
(67,803
)
Operating income (loss) from continuing operations
 
562,675

 
129,218

 
(244,715
)
 
447,178

2011:
 
 

 
 

 
 

 
 

Net sales
 
$
5,123,477

 
$
1,044,191

 
$
15,254

 
$
6,182,922

Depreciation and amortization expense
 
(64,484
)
 
(16,221
)
 
(52,427
)
 
(133,132
)
Settlement, litigation and other related charges
 
(55,031
)
 
(643
)
 
—

 
(55,674
)
Other charges, net
 
(15,049
)
 
—

 
(1,044
)
 
(16,093
)
Operating income (loss) from continuing operations
 
476,800

 
98,938

 
(142,795
)
 
432,943

2010:
 
 

 
 

 
 

 
 

Net sales
 
$
5,175,730

 
$
838,790

 
$
16,150

 
$
6,030,670

Depreciation and amortization expense
 
(58,271
)
 
(17,094
)
 
(75,181
)
 
(150,546
)
Settlement, litigation and other related charges
 
(113,279
)
 
(430
)
 
—

 
(113,709
)
Other charges, net
 
(13,745
)
 
(14,173
)
 
(119,313
)
 
(147,231
)
Operating income (loss) from continuing operations
 
374,110

 
75,039

 
(259,995
)
 
189,154


The Company's continuing operations were primarily located in the United States with one pharmacy located in Canada which was not material to the consolidated sales or total assets of Omnicare and was disposed of in the third quarter of 2012.